Investorideas.com newswire, breaking biotechnology and pharma news

Thursday, June 25, 2015

Media Alert for Vycor Medical, Inc. (OTCQB: VYCO);” Vycor Medical Offers Upside Through Vision Therapy” - Portfolio Guru

Media Alert for Vycor Medical, Inc. (OTCQB: VYCO);” Vycor Medical Offers Upside Through Vision Therapy” - Portfolio Guru

Point Roberts WA, NEW YORK, NY -- June 25, 2015 - Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a media alert for Vycor Medical, Inc (OTCQB:VYCO) and its NovaVision Vision Restoration Therapy. The company was recently featured in articles by Jim Collins, Portfolio Guru, LLC, published at TheStreet.com.

Articles:
An Eye for EYES, and Here's Why
TheStreet.com-Jun 19, 2015
Jim Collins

Today I'll return to one of my favorite ideas, Second Sight Medical ... I'll focus on another company in the vision field, Vycor Medical (VYCO). http://realmoney.thestreet.com/articles/06/19/2015/eye-eyes-and-heres-why

Follow up Article: Vycor Medical Offers Upside Through Vision Therapy
Jim Collins
Portfolio Guru, LLC
www.theportfolioguru.com

I wrote in Friday's column about Second Sight, whose Argus II retinal implant restores sight in patients with retinitis pigmentosa and will soon enter clinical trials for age-related macular degeneration. Both conditions are obviously degenerative, but what happens when sight is impaired due to a sudden condition? Two common causes of this would be stroke and traumatic brian injury (TBI).

That's where Vycor Medical (VYCO) comes in. The company's NovaVision suite of therapies offer ability to improve quality of vision--and thus quality of life--in patients who have suffered stroke or TBI.

Link to article:


About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB—VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge.  VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical’s VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments.  The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from Stroke, Traumatic Brain Injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any physician.  VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed NeuroEyeCoach™, a therapy which is highly complementary to VRT™. The two therapies address different visual disabilities each of which results from neurologically-induced vision loss – a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach™ is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. 

See the video on YouTube.com - NovaVision Vision Restoration Therapy


For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

InvestorIdeas.com newswire is a global investor news source covering leading sectors including medical technology and biotech.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Vycor (OTCQB:VYCO) Announces Commercial Release of Its NovaVision Web Deliverable Therapy Suite

"We are now finally in a position to deliver our therapies to the large numbers of people who suffer vision loss as a result of neurological brain damage as a cost effective and complete therapy solution" - CEO of Vycor

BOCA RATON, Florida - June 25, 2015 (Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the commercial release of its Internet-delivered therapy suite in the U.S. This therapy suite, consisting of its lead Vision Restoration Therapy (VRT) and its NeuroEyeCoach eye-movement compensation therapy, is delivered directly to patients over the Internet onto their own computers replacing the Company's current "prototype hardware centric" model.

NovaVision has been working to take its VRT therapy prototype and develop it into an affordable, scalable therapy offering that offers broader patient benefits. VRT will going forward be provided alongside NovaVision's NeuroEyeCoach compensatory therapy in one Internet delivered therapy suite. Two things happen when someone suffers from vision related disorders following a stroke or brain injury: there is a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT addresses the restoration of lost vision while NeuroEyeCoach addresses patients' difficulty with their eye movements and their ability to integrate visual information, allowing them to make the most of their remaining vision, The two therapies provided in a suite are therefore highly complementary and ensure broad benefits to NovaVision's patients.

NovaVision is now positioned, for the first time, with the suite of therapies and product offerings to deliver on its strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering visual impairment following neurological damage; and to offer solutions for both patients and physicians alike.

For Patients:
·        VRT and NeuroEyeCoach Therapy Suite. NovaVision will commercially launch this week these two complementary therapies, internet-delivered in a package for $900.
·        NeuroEyeCoach. For patients with visual impairments who are not suitable, for whatever reason, for VRT, NovaVision provides NeuroEyeCoach on its own for $450.

For Physicians:
·        Vision Diagnostic (VIDIT). The diagnostic component of VRT that enables therapists to perform high-resolution visual field tests in less than 10 minutes to screen for visual field deficits.
·        NeuroEyeCoach Pro Center. Enables stroke rehabilitation and other centers to treat patients while in their care, both as in-patient and out-patient.
·        NovaVision and NeuroEyeCoach Pro Physician. Enables physicians to register patients in their clinic who complete the therapy at home, supported by NovaVision but monitored by the physician through a dedicated portal.

VRT is a prescription product and the only FDA cleared therapy (510k) for the restoration of vision loss from neurological damage. VRT is supported by 15 years of clinical research and over 20 studies including a 302 patient study in which notable improvements were seen in 70% of the patients. NeuroEyeCoach is also clinically supported being based on research that has been the subject of 14 clinical studies on a total of 591 patients and has FDA registration.

Commenting on the Company's announcement, Peter Zachariou, CEO of Vycor, stated: "This has been a long time coming and has entailed an enormous amount of work from both our employees but also our scientific advisors and is a key milestone for NovaVision. We are now finally in a position to deliver our therapies to the large numbers of people who suffer vision loss as a result of neurological brain damage as a cost effective and complete therapy solution. I am convinced that this new therapy suite is the most robust, affordable and complete commercially available visual therapy solution targeted at this type of vision loss.
This also represents the final step in moving NovaVision from being a development company to one focused on commercializing its unique suite of products. I would urge anyone who has had a stroke or brain injury and suffers from a visual disorder to contact us, we have numerous testimonials of patients for whom these therapies have literally changed their lives".

There are approximately 8m stroke survivors in the U.S. with 795,000 strokes a year, and approximately 1.5m suffering some sort of Traumatic Brain Injury (TBI) annually; up to 30% of these suffer a resultant visual impairment, up to 20% permanently. In all, around 2.8 million Americans suffer from this type of vision impairment, which is largely unaddressed by the rehabilitation system. The impact on their daily lives is dramatic, and is the difference between a person being able to be home alone, cross the road unaided, drive, shop or read. The new therapy suite is targeted at this largely underserved group of people.

For an overview of NovaVision see NovaVision Video.


About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical's ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss - a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.comwww.vycorvbas.com or www.novavision.com.

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor Medical, Inc. Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

For more information on VYCO on Investorideas, please visit: http://www.investorideas.com/CO/VYCO/


Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Vycor Medical Inc. (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.





Thursday, June 18, 2015

Video Alert: Vycor Medical, Inc. (OTCQB:VYCO) NovaVision Vision Restoration Therapy

One of the only solutions for victims of stroke and brain injury

Point Roberts WA, NEW YORK, NY -- June 18, 2015 - Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a video alert for Vycor Medical, Inc (OTCQB:VYCO) featuring its NovaVision Vision Restoration Therapy. The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from Stroke, Traumatic Brain Injury (TBI), or other acquired brain injuries.

See the video on YouTube.com - NovaVision Vision Restoration Therapy



About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB—VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge.  VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical’s VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments.  The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from Stroke, Traumatic Brain Injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any physician.  VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed NeuroEyeCoach™, a therapy which is highly complementary to VRT™. The two therapies address different visual disabilities each of which results from neurologically-induced vision loss – a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach™ is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side.  For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

InvestorIdeas.com newswire is a global investor news source covering leading sectors including medical technology and biotech.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Monday, June 15, 2015

CEO of Vycor Medical, Inc. (VYCO) Discusses Recent Agreement with HealthSouth for NovaVision’s NeuroEyeCoach Eye Compensation Therapy

CEO of Vycor Medical, Inc. (VYCO) Discusses Recent Agreement with HealthSouth for NovaVision’s NeuroEyeCoach Eye Compensation Therapy

Vycor Medical’s NovaVision Vision Therapy Provides Unique Solution for Millions of Stroke and Brain Injury Patients Afflicted with Visual Disorders

Point Roberts WA, NEW YORK, NY -- June 15, 2015 - Investorideas.com, a global news source covering leading sectors including biotech and medical technology releases an exclusive interview with Peter Zachariou, CEO of Vycor Medical, Inc (VYCO).  Peter discusses the recent agreement with HealthSouth for its NovaVision NeuroEyeCoach Professional Center therapy program.

This agreement follows the earlier approval by HealthSouth for Vycor Medical’s NovaVision VIDIT. NovaVision’s lead therapy, Vision Restoration Therapy (VRT), has both a diagnostic (VIDIT) and a therapeutic component. It is this diagnostic component that is being made available to HealthSouth participating hospitals to enable HealthSouth rehabilitation and clinical teams to perform high resolution visual field tests to screen for central visual field deficits commonly associated with Stroke or Brain Injury.

HealthSouth’s interest in NovaVision’s therapies demonstrates that vision is increasingly being recognized as an important condition alongside speech, occupational and physical therapies.

“According to the CDC, every 40 seconds someone has a Stroke. Nearly 2 million people sustain a Traumatic Brain Injury (TBI) per year in the U.S. alone. The Stroke Association estimates there are 8 Million Stroke survivors and approximately 20% of both Stroke and TBI survivors suffer some form of permanent vision loss.”
 
Peter shares insight into this game-changing technology and how the agreements with HealthSouth will play an integral role in the future of bringing vision therapy products to patients.


Q: Investorideas.com
Peter, for investors that are not familiar with your company and its technology, can you give an overview of the NovaVision suite of products and the relationship between Vycor Medical and NovaVision?

A: Peter Zachariou, CEO of Vycor Medical, Inc.
NovaVision is a wholly-owned subsidiary of Vycor Medical. NovaVision provides a comprehensive family of therapies designed for patients with neurologically induced visual disorders. The suite of therapies both restore (VRT) and help to compensate (NeuroEyeCoach) for lost vision and complement each other to maximize patient benefit. NovaVision’s diagnostic and therapy programs have FDA clearance.

All of NovaVision’s therapies are supported by clinical data. NovaVision’s lead therapy, Vision Restoration Therapy (VRT), is the only FDA cleared therapy targeted at the restoration of lost vision as a result of neurological brain damage such as that caused by a Stroke or Traumatic Brain Injury (TBI). VRT is underpinned by 15 years of research and over 20 clinical studies.
We estimate that the market potential for NovaVision’s therapies in the US and Europe alone is around $4 Billion.


Q: Investorideas.com
In your most recent press release you announced your second agreement with HealthSouth, now placing both NeuroEyeCoach, your eye movement compensation therapy and your diagnostic technology (NovaVision’s VRT) at HealthSouth. What does this mean in terms of patient treatment?

A: Peter Zachariou, CEO of Vycor Medical, Inc
Visual field deficits caused by neurological injuries can result in a debilitating loss of confidence and cause significant isolation; activities of daily life such as reading, shopping or driving can be very negatively affected.

The VIDIT agreement with HealthSouth participating hospitals provides their therapists with the tools to identify if a patient has a visual disorder. The therapist then has the opportunity to refer the patient to NovaVision for the treatment of these disorders.

It is important to note that prior to the development of VRT, there was no commercially available therapy to improve the range or sensitivity of the patient’s field of vision – patients were told they “had to live with” their deficits. This has now been clinically proven not to be true.

The significance of being able to quickly identify visual disorders through this effective screening program is highlighted by the fact that approximately one-third of Stroke or Brain Injury patients will suffer from a neurologically-induced visual disorder. An undetected visual field deficit may adversely impact other rehabilitation modalities. Early detection and treatment are critical steps towards improving overall patient care. Our product offering now available to the HealthSouth network allows their therapists to both identify vision loss and help patients compensate for their loss.

To carry out normal daily tasks, such as finding an object at home or on a supermarket shelf, you need to make effective eye movements. Unfortunately, normal eye movements are also affected after Brain Injury adding to the problems of blindness. Specific training is needed for you to learn to make effective use of your eye movement again. While VRT has been shown to actually restore some of a patients lost vision, our NeuroEyeCoach program increases the efficiency of a patient’s eye movement and re-trains the patients’ ability to make the most of their remaining vision. The two therapies are therefore highly complementary and provide broad benefits.


Q: Investorideas.com
Can you give us some background on this most recent HealthSouth agreement and the steps moving forward?

A: Peter Zachariou, CEO of Vycor Medical, Inc.
HealthSouth trialed both the products for many months in several sites and collected feedback. On the basis of the feedback, HealthSouth approved our products to be made available in their network.

We have placed VIDIT products with several HealthSouth hospitals and are now actively marketing our VIDIT and NeuroEyeCoach products through the HealthSouth network.

The significance of this strategy is that most patients who have suffered a Stroke or significant Traumatic Brain Injury (TBI) will touch a rehab center as an inpatient or outpatient at some time and that is the universe of patients that are eligible for our therapies.

Looking beyond HealthSouth, there are other rehabilitation chains in the US which also may be interested in providing more focused vision rehabilitation treatments. NovaVision stands ready to service those other chains also.


Q: Investorideas.com
Can you share some success stories and statistics of the vision therapy technology?

A: Peter Zachariou, CEO of Vycor Medical, Inc.
One of the most gratifying aspects of my job is that we have a large number of success stories of people who have undertaken both our VRT and our NeuroEyeCoach therapies. You may have heard most recently of Carol Urban who has given a number of radio interviews on how she got her life back following VRT. Carol is a good example of how these therapies can change someone’s life. In her case, her physician actually told her that it wouldn’t work and she has now got over 90% of her vision back.

One thing we haven’t touched on is our therapy suite and how it is readily available to everyone who has suffered visual disorders following some sort of brain damage such as Stroke. Our VRT and NeuroEyeCoach will very shortly be available to patients in their own home - delivered over the Internet onto their own computers, at a very affordable price. We believe this is the most affordable, clinically supported, comprehensive therapy suite available on the market to address visual disorders from neurological brain damage. I would urge anyone who has suffered vision loss of this kind to reach out to NovaVision.


Q: Investorideas.com
Vycor’s NovaVision is currently the only FDA approved vision therapy product. What does that mean for the company in terms of market opportunity?

A: Peter Zachariou, CEO of Vycor Medical, Inc.
NovaVision provides non-invasive, computer-based vision solutions targeted at a substantial and largely unaddressed market of people who have visual disorders as a result of Stroke, Traumatic Brain Injury (TBI) or other neurological brain damage.

Unfortunately that translates into many millions of people who suffer from this kind of vision loss. Every 40 seconds someone in the US has a Stroke and there are about 795,000 strokes a year and 8 million American’s who have suffered a Stroke. Up to 30% of these have a visual disorder and 20% a permanent visual field deficit. You can quickly appreciate that the market we are targeting is in the many billions of dollars and as you say, VRT is the only clinically supported restoration therapy out there with FDA clearance.

Q: Investorideas.com
In closing, can you summarize your corporate strategy and vision that includes your complete portfolio of products and medical solutions?

A: Peter Zachariou, CEO of Vycor Medical, Inc.
To date, NovaVision’s products have changed the lives of many patients. It is our clear intention to continue to promote and raise the awareness of our life-improving therapies with a view of becoming the gold standard for vision rehabilitation for patients who have suffered visual disorders resulting from Stroke and other brain injuries.

Since Vycor acquired NovaVision, we have focused on building the basis for this gold standard objective by driving down the price of the therapy by lowering the cost of delivery and increasing efficiencies; broadening benefits to patients by adding NeuroEyeCoach; and making our therapies truly scalable. NovaVision is now positioned for the first time, with the suite of therapies and product offerings, to deliver on this strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering visual impairment following neurological damage and to offer solutions for both patients and physicians alike.

About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB—VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge.  VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical’s VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments.  The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from Stroke, Traumatic Brain Injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any physician.  VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed NeuroEyeCoach™, a therapy which is highly complementary to VRT™. The two therapies address different visual disabilities each of which results from neurologically-induced vision loss – a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach™ is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side.  For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

InvestorIdeas.com newswire is a global investor news source covering leading sectors including medical technology and biotech.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Monday, June 8, 2015

Vycor (OTCQB:VYCO) Signs Agreement with HealthSouth (NYSE:HLS) for Second NovaVision Therapy Product

Vycor (OTCQB:VYCO) Signs Agreement with HealthSouth (NYSE:HLS) for Second NovaVision Therapy Product

BOCA RATON, Florida - June 8, 2015 (Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it has entered into an agreement with HealthSouth Corporation (NYSE:HLS) to make available its NeuroEyeCoach Professional Center therapy program to participating HealthSouth hospitals, following a 3-month trial of the therapy in two HealthSouth locations.

NeuroEyeCoach is NovaVision's eye movement compensation therapy for those patients who have suffered a cerebral visual field disorder as a result of a stroke or brain injury and is designed to improve a patient's ability to scan their environment more efficiently. The program is based on several decades of scientific research pioneered by Professor Josef Zihl at the Max Planck Institute in Munich that has been the subject of numerous clinical studies. Participating HealthSouth hospitals will use the program to treat patients while in their care. In contrast to other clinic-based saccadic programs, NeuroEyeCoach is a full-course therapy dedicated to cerebral visual field disorders and can be continued by the patient in their home environment.

This agreement follows the approval by HealthSouth in late 2014 to make available its VIDIT diagnostic to their hospital network and NovaVision is installing devices into this network. The NovaVision VIDIT is the diagnostic component of the Company's Vision Restoration Therapy (VRT) and is used to perform high-resolution visual field tests to screen for central visual field deficits commonly associated with stroke or brain injury. The ability for Health South physicians to be able to quickly identify visual disorders through the effective screening program is highlighted by the fact that approximately one-third of stroke or other brain injury patients suffer from a neurologically induced visual disorder and if this deficit goes undetected it may adversely impact other rehabilitation modalities. Early detection and treatment are critical steps towards improving overall patient care, a key objective of HealthSouth.

Once diagnosed, patients are able to be treated in-clinic with NeuroEyeCoach and referred to NovaVision for treatment following discharge at home using VRT, which is the only FDA cleared clinically supported therapy targeted at the restoration of lost vision resulting from neurological brain damage such as that resulting from stroke.

HealthSouth (www.healthsouth.com) is one of the largest providers of post-acute healthcare services in the U.S. These two agreements therefore provide NovaVision with a source of installation and rental income but equally as important is a potentially large source of patients; most stroke patients will touch a rehabilitation center at some point and HealthSouth is the largest network of stroke rehabilitation hospitals in the U.S.

This announcement follows NovaVision's press release in March that it had completed development of VRT 7.0, re-engineering the therapy to be internet-delivered and streamlining business process to enable a significant reduction in cost to the patient.
NovaVision will provide VRT and NeuroEyeCoach in one therapy suite. NovaVision will very shortly be commencing accepting patients with the new therapy suite which is considered by management to be the most affordable, clinically supported, comprehensive therapy suite available on the market to address visual disorders arising from stroke or brain injury.


About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical's ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss - a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.comwww.vycorvbas.com or www.novavision.com.

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor Medical, Inc. Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

For more information on VYCO on Investorideas, please visit: http://www.investorideas.com/CO/VYCO/


Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Vycor Medical Inc. (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.